Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 28

Circulation

Background: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are foundational therapy in patients with heart failure with reduced ejection fraction (HFrEF), yet underlying mechanisms of benefit